[go: up one dir, main page]

GB0403600D0 - Methods and reagents for treating disease - Google Patents

Methods and reagents for treating disease

Info

Publication number
GB0403600D0
GB0403600D0 GBGB0403600.0A GB0403600A GB0403600D0 GB 0403600 D0 GB0403600 D0 GB 0403600D0 GB 0403600 A GB0403600 A GB 0403600A GB 0403600 D0 GB0403600 D0 GB 0403600D0
Authority
GB
United Kingdom
Prior art keywords
reagents
methods
treating disease
disease
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0403600.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRINITY OF QUEEN ELIZABETH NEA
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
TRINITY OF QUEEN ELIZABETH NEA
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRINITY OF QUEEN ELIZABETH NEA, College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical TRINITY OF QUEEN ELIZABETH NEA
Priority to GBGB0403600.0A priority Critical patent/GB0403600D0/en
Publication of GB0403600D0 publication Critical patent/GB0403600D0/en
Priority to PCT/GB2005/000626 priority patent/WO2005079815A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01205—IMP dehydrogenase (1.1.1.205)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0403600.0A 2004-02-18 2004-02-18 Methods and reagents for treating disease Ceased GB0403600D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0403600.0A GB0403600D0 (en) 2004-02-18 2004-02-18 Methods and reagents for treating disease
PCT/GB2005/000626 WO2005079815A2 (en) 2004-02-18 2005-02-17 Methods and reagents for treating autosomal dominant diseases of the eye

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0403600.0A GB0403600D0 (en) 2004-02-18 2004-02-18 Methods and reagents for treating disease

Publications (1)

Publication Number Publication Date
GB0403600D0 true GB0403600D0 (en) 2004-03-24

Family

ID=32039955

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0403600.0A Ceased GB0403600D0 (en) 2004-02-18 2004-02-18 Methods and reagents for treating disease

Country Status (2)

Country Link
GB (1) GB0403600D0 (en)
WO (1) WO2005079815A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781787T3 (en) 2004-08-23 2018-01-31 Sylentis Sau Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
TWI386225B (en) 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
TWI401316B (en) * 2004-12-23 2013-07-11 Alcon Inc Rnai inhibition of serum amyloid a for treatment of glaucoma
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
US7947660B2 (en) 2005-03-11 2011-05-24 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP2015533792A (en) 2012-09-05 2015-11-26 シレンティス・エセ・ア・ウ siRNA and its use in methods and compositions for the treatment and / or prevention of ocular conditions
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
RU2746991C2 (en) * 2014-09-16 2021-04-23 Джензим Корпорейшн Adeno-associated viral vectors for treatment of myocilin (myoc) glaucoma
EP4012035B1 (en) * 2014-09-16 2024-11-06 Genzyme Corporation Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
HUE070278T2 (en) * 2014-09-16 2025-05-28 Genzyme Corp Adeno-associated viral vectors for treating myocilin (myoc) glaucoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
WO2004022782A2 (en) * 2002-09-04 2004-03-18 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs

Also Published As

Publication number Publication date
WO2005079815A3 (en) 2006-04-27
WO2005079815A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
IL182837A0 (en) Methods, assays and compositions for treating retinol-related diseases
IL175818A0 (en) Method for treating adamts-5- associated disease
IL182011A0 (en) Treatment screening methods
PL1771201T3 (en) Compositions and methods for treating or preventing oxalate-related disease
IL183059A0 (en) Cancer treatment method
IL179323A0 (en) Cancer treatment method
GB0403600D0 (en) Methods and reagents for treating disease
GB0427821D0 (en) Catalyst and process
EP1755394A4 (en) Cancer treatment method
GB0417263D0 (en) Process and system
IL179359A0 (en) Cancer treatment method
PT1611890E (en) Methods for assessing and treating cancer
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
EP1812850A4 (en) Efficient multiprocessor system and methods thereof
GB0414233D0 (en) Analysis method
GB0424552D0 (en) Methods and means
EP1809276A4 (en) Treatment method
GB0403847D0 (en) Methods and means
EP1802617A4 (en) Cancer treatment method
GB0408156D0 (en) Process and compounds
GB0421911D0 (en) Methods and means
GB0520405D0 (en) Biological agents and method
GB0406800D0 (en) Microarray method
EP1773406A4 (en) Method for screening agents against human prostate disease
GB0522732D0 (en) Composition and method for treating disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)